OncoSec Medical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for OncoSec Medical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	28.5%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

OncoSec to cut workforce by 45% as part of corporate restructuring

Oct 04

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

Jan 28

Dosing underway in OncoSec's Tavo combo trial in skin cancer

Jan 08

OncoSec: Undervalued And Continuing To Make Progress

Nov 18

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

Nov 09

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as OncoSec Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:ONCS.Q - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
1/31/2023	N/A	-29	-25	-25	N/A
10/31/2022	N/A	-32	-29	-28	N/A
7/31/2022	N/A	-34	-32	-32	N/A
4/30/2022	N/A	-38	-34	-34	N/A
1/31/2022	N/A	-41	-42	-41	N/A
10/31/2021	N/A	-42	-43	-42	N/A
7/31/2021	N/A	-45	-43	-42	N/A
4/30/2021	N/A	-42	-44	-43	N/A
1/31/2021	N/A	-43	-38	-38	N/A
10/31/2020	N/A	-46	-35	-35	N/A
7/31/2020	N/A	-42	-33	-33	N/A
4/30/2020	N/A	-41	-32	-32	N/A
1/31/2020	N/A	-38	-31	-31	N/A
10/31/2019	N/A	-32	-30	-30	N/A
7/31/2019	N/A	-30	-29	-29	N/A
4/30/2019	N/A	-35	-27	-27	N/A
1/31/2019	N/A	-38	-25	-25	N/A
10/31/2018	N/A	-41	-25	-25	N/A
7/31/2018	N/A	-39	-23	-23	N/A
4/30/2018	N/A	-33	-22	-22	N/A
1/31/2018	N/A	-27	-20	-20	N/A
10/31/2017	N/A	-22	-18	-18	N/A
7/31/2017	N/A	-21	-17	-17	N/A
4/30/2017	N/A	-22	-17	-17	N/A
1/31/2017	N/A	-24	-18	-17	N/A
10/31/2016	N/A	-25	N/A	-18	N/A
7/31/2016	N/A	-27	N/A	-18	N/A
4/30/2016	N/A	-27	N/A	-19	N/A
1/31/2016	N/A	-27	N/A	-19	N/A
10/31/2015	N/A	-24	N/A	-19	N/A
7/31/2015	N/A	-21	N/A	-18	N/A
4/30/2015	N/A	-18	N/A	-15	N/A
1/31/2015	N/A	-16	N/A	-13	N/A
10/31/2014	N/A	-14	N/A	-10	N/A
7/31/2014	N/A	-12	N/A	-9	N/A
4/30/2014	N/A	-10	N/A	-8	N/A
1/31/2014	N/A	-8	N/A	-7	N/A
10/31/2013	N/A	-7	N/A	-6	N/A
7/31/2013	N/A	-7	N/A	-6	N/A
4/30/2013	N/A	-7	N/A	-6	N/A
1/31/2013	N/A	-6	N/A	-5	N/A
10/31/2012	N/A	-7	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ONCS.Q's forecast earnings growth is above the savings rate (2.1%).

Earnings vs Market: Insufficient data to determine if ONCS.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ONCS.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ONCS.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ONCS.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ONCS.Q's Return on Equity is forecast to be high in 3 years time

OncoSec Medical Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$5.00

Price target decreased to US$5.00

Forecast to breakeven in 2024

Price target raised to US$8.13

Recent updates

OncoSec Medical Incorporated Announces Termination of George Chi as Chief Financial Officer

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $1.330923 million.

Oncosec Medical Incorporated Announces Type C Meeting with the US Food and Drug Administration to Discuss Proposed Neoadjuvant Melanoma Clinical Program

High number of new directors

OncoSec Medical Incorporated Receives Notice from the Nasdaq Stock Market LLC

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated has completed a Follow-on Equity Offering.

OncoSec Medical Incorporated Presents Encouraging Early Data with TAVO™-EP combined with Nivolumab (Opdivo®) in Neoadjuvant Melanoma

Oncosec Medical Incorporated Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-Ep in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to Anti-Pd-1 Treatment

OncoSec Medical Incorporated Elects Robert H. Arch as Non-Independent Director of the Board

OncoSec Medical Incorporated Elects Stephany Foster as an Independent Director

OncoSec Medical Incorporated Announces Workforce Reduction

OncoSec to cut workforce by 45% as part of corporate restructuring

OncoSec Medical Incorporated Appoints Joon Kim to the Audit Committee

OncoSec Medical Incorporated, Annual General Meeting, Nov 23, 2022

OncoSec Medical Receives Notice from Nasdaq Regarding Minimum Bid Price Requirement

OncoSec Medical Incorporated Appoints Robert H. Arch as Chief Executive Officer

Price target decreased to US$5.00

Less than half of directors are independent

OncoSec Medical Incorporated, Annual General Meeting, Jul 12, 2022

Price target decreased to US$5.00

OncoSec Medical Incorporated Announces Appointment of George Chi as Chief Financial Officer

Oncosec Medical Receives Notice from the Nasdaq Stock Market

Less than half of directors are independent

Interim CEO & COO Brian Leuthner has left the company

Forecast to breakeven in 2024

President, CEO & Director Daniel O'Connor has left the company

OncoSec Medical Incorporated, Annual General Meeting, Apr 29, 2021

Price target raised to US$8.13

OncoSec Medical Incorporated Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, Tavo™, in Triple Negative Breast Cancer

OncoSec Medical Incorporated Appoints Bridget O'keeffe as Vice President of Clinical Development

OncoSec Medical Incorporated Announces Management Appointments

New 90-day high: US$7.71

OncoSec Announces First Subjects Dosed in Phase 1 Trial of Corvax12, Oncosec's Covid-19 Vaccine Candidate Combining Interleukin-12 (Il-12) with an Enhanced Sars-Cov-2 Spike Protein

What Type Of Shareholders Make Up OncoSec Medical Incorporated's (NASDAQ:ONCS) Share Registry?

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $42.026498 million.

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

New 90-day high: US$6.81

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Dosing underway in OncoSec's Tavo combo trial in skin cancer

New 90-day high: US$6.65

OncoSec Medical Incorporated Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO and its Gene Electrotransfer Technology

OncoSec Medical Incorporated Announces Exclusive License Agreement for Cliniporator Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics

OncoSec: Undervalued And Continuing To Make Progress

OncoSec Announces Positive Interim Data from KEYNOTE-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at SITC 2020

OncoSec drops 11% despite positive data from TAVO + Merck's Keytruda in metastatic melanoma

New 90-day high: US$5.11

OncoSec Medical Incorporated to Present Positive Interim Data from Keynote-695 Trial in Anti-PD-1 Checkpoint Refractory Metastatic Melanoma

OncoSec Announces FDA Clearance of IND Application for Initiation of Phase 1 Clinical Trial of its CORVax12 Vaccine Candidate for COVID-19

OncoSec Medical Incorporated Announces Stepping Down of Kellie Malloy Foerter as Chief Operating Officer

OncoSec Medical Incorporated Announces Appointment of Sandra Aung as Senior Vice President, Chief Clinical Development Officer

OncoSec Announces Issuance of New U.S. Patent Expanding Coverage of TAVO and Its Gene Delivery Platform

OncoSec Medical Incorporated has completed a Follow-on Equity Offering in the amount of $14.977914 million.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies